» Articles » PMID: 32605184

Early Elevation of Systemic Plasma Clusterin After Reperfused Acute Myocardial Infarction in a Preclinical Porcine Model of Ischemic Heart Disease

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Jul 2
PMID 32605184
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Clusterin exerts anti-inflammatory, cytoprotective and anti-apoptotic effects. Both an increase and decrease of clusterin in acute myocardial infarction (AMI) has been reported. We aimed to clarify the role of clusterin as a systemic biomarker in AMI. AMI was induced by percutaneous left anterior artery (LAD) occlusion for 90 min followed by reperfusion in 24 pigs. Contrast ventriculography was performed after reperfusion to assess left ventricular ejection fraction (LVEF), left ventricular end diastolic volume (LVEDV) and left ventricular end systolic volume (LVESV) and additional cMRI + late enhancement to measure infarct size and LV functions at day 3 and week 6 post-MI. Blood samples were collected at prespecified timepoints. Plasma clusterin and other biomarkers (cTnT, NT-proBNP, neprilysin, NGAL, ET-1, osteopontin, miR21, miR29) were measured by ELISA and qPCR. Gene expression profiles of infarcted and remote region 3 h ( = 5) and 3 days ( = 5) after AMI onset were analysed by RNA-sequencing. AMI led to an increase in LVEDV and LVESV during 6-week, with concomitant elevation of NT-proBNP 3-weeks after AMI. Plasma clusterin levels were increased immediately after AMI and returned to normal levels until 3-weeks. Plasma NGAL, ET-1 and miR29 was significantly elevated at 3 weeks follow-up, miR21 increased after reperfusion and at 3 weeks post-AMI, while circulating neprilysin levels did not change. Elevated plasma clusterin levels 120 min after AMI onset suggest that clusterin might be an additional early biomarker of myocardial ischemia.

Citing Articles

The pig as an optimal animal model for cardiovascular research.

Jia H, Chang Y, Song J Lab Anim (NY). 2024; 53(6):136-147.

PMID: 38773343 DOI: 10.1038/s41684-024-01377-4.


High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction.

Carmo H, Bonilha I, Barreto J, Tognolini M, Zanotti I, Sposito A Int J Mol Sci. 2024; 25(2).

PMID: 38279290 PMC: 10816227. DOI: 10.3390/ijms25021290.


Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions.

Bozkurt B, Nair A, Misra A, Scott C, Mahar J, Fedson S JACC Basic Transl Sci. 2023; 8(1):88-105.

PMID: 36777165 PMC: 9911324. DOI: 10.1016/j.jacbts.2022.05.010.

References
1.
Anand I, Fisher L, Chiang Y, Latini R, Masson S, Maggioni A . Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003; 107(9):1278-83. DOI: 10.1161/01.cir.0000054164.99881.00. View

2.
Nymo S, Hartford M, Ueland T, Yndestad A, Lorentzen E, Truve K . Serum neutrophil gelatinase-associated lipocalin (NGAL) concentration is independently associated with mortality in patients with acute coronary syndrome. Int J Cardiol. 2018; 262:79-84. DOI: 10.1016/j.ijcard.2018.03.028. View

3.
Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S . Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009; 361(9):858-67. DOI: 10.1056/NEJMoa0900428. View

4.
Kafkas N, Demponeras C, Zoubouloglou F, Spanou L, Babalis D, Makris K . Serum levels of gelatinase associated lipocalin as indicator of the inflammatory status in coronary artery disease. Int J Inflam. 2012; 2012:189797. PMC: 3440856. DOI: 10.1155/2012/189797. View

5.
Kumar D, Narang R, Sreenivas V, Rastogi V, Bhatia J, Saluja D . Circulatory miR-133b and miR-21 as Novel Biomarkers in Early Prediction and Diagnosis of Coronary Artery Disease. Genes (Basel). 2020; 11(2). PMC: 7073535. DOI: 10.3390/genes11020164. View